Catalase activity and arsenic sensitivity in acute leukemia.

Abstract

Arsenic trioxide (As2O3) is currently employed as a treatment for relapsed acute promyelocytic leukemia (APL), where it can induce remission in greater than 90% of patients, but is ineffective in patients with non-APL acute myeloid leukemia (AML). As2O3 induces apoptosis in APL cells through mechanisms dependent and independent of the PML-RARalpha fusion… (More)
DOI: 10.1080/10428190802353617

Topics

Cite this paper

@article{Coe2008CatalaseAA, title={Catalase activity and arsenic sensitivity in acute leukemia.}, author={Emma Coe and Aaron David Schimmer}, journal={Leukemia & lymphoma}, year={2008}, volume={49 10}, pages={1976-81} }